Trial Profile

A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Combinations in Adult Patients With Myelofibrosis

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Decitabine (Primary) ; Nisevokitug (Primary) ; Sabatolimab (Primary) ; Spartalizumab (Primary)
Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
Focus Therapeutic Use
Sponsors Novartis Pharmaceuticals

Most Recent Events

08 Jan 2021 Status changed from recruiting to withdrawn prior to enrolment.
17 Nov 2020 Planned initiation date (estimated date for recruitment of the first subject) changed from 15 Sep 2020 to 30 Nov 2020.
17 Nov 2020 Planned initiation date changed from 15 Sep 2020 to 30 Nov 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com